What is the recommended initial treatment for asthma, including a short‑acting β2‑agonist (SABA) rescue medication and a low‑dose inhaled corticosteroid (ICS) for daily control?

Initial Asthma Treatment

For initial asthma treatment, all patients should receive an inhaled corticosteroid (ICS)-containing regimen and should NOT be treated with a short-acting β2-agonist (SABA) alone. 1, 2

Recommended Treatment Approach by Age

Adults and Adolescents (≥12 years)

Preferred Strategy (Track 1):

• As-needed low-dose ICS-formoterol combination inhaler serves as both rescue medication and provides anti-inflammatory control 1, 2, 3
• This approach markedly decreases severe asthma exacerbations compared to SABA alone 3
• Eliminates the adherence problem of separate maintenance and rescue inhalers 4

Alternative Strategy (Track 2):

• Daily low-dose ICS (100-250 μg fluticasone propionate equivalent) PLUS as-needed SABA for rescue 1
• For mild persistent asthma, either daily low-dose ICS with as-needed SABA OR as-needed ICS-SABA used concomitantly are conditionally recommended 1
• The recently FDA-approved ICS-albuterol combination (2023) provides another option for as-needed use 5, 3

Children Ages 5-11 Years

• Daily low-dose ICS (preferred) with as-needed SABA 1
• Alternative: Daily montelukast with as-needed SABA (though FDA issued a Boxed Warning for montelukast in March 2020) 1
• For step 3 treatment in 4-year-olds, medium-dose ICS with as-needed SABA is preferred 1

Children Ages 0-4 Years

• Daily low-dose ICS with as-needed SABA is the preferred initial treatment 1
• For recurrent wheezing triggered only by respiratory tract infections with no wheezing between infections: conditionally recommend starting a short course of daily ICS at the onset of respiratory infection with as-needed SABA 1
• Alternative: Daily montelukast with as-needed SABA 1

Critical Dosing Considerations

The "low-dose" ICS terminology is evidence-based:

• Low-dose ICS (200-250 μg fluticasone propionate equivalent) achieves 80-90% of maximum therapeutic benefit 6
• This represents the optimal starting dose for most patients 6
• Higher doses provide minimal additional benefit but significantly increase systemic adverse effects 6

Why SABA Monotherapy Is No Longer Recommended

SABA-only treatment carries substantial risks:

• Provides no anti-inflammatory effect, allowing ongoing airway inflammation 7, 4
• Poor adherence to separate maintenance ICS leads patients to revert to SABA-only use, increasing exacerbation risk 7, 4
• Overuse of SABA (>2 days/week for symptom relief) indicates inadequate control 1
• Associated with poor asthma outcomes and increased mortality risk 2, 3

Common Pitfalls to Avoid

Insurance coverage represents the main practice barrier:

• Incomplete insurance coverage for ICS-formoterol combination inhalers is frequently cited as the primary hurdle 8
• Insurance may not approve more than one canister of ICS-formoterol per month, limiting SMART strategy implementation 8
• Cost considerations may necessitate using the alternative Track 2 approach with separate ICS maintenance and SABA rescue 8

Prescribing errors to avoid:

• Do not prescribe ICS-salmeterol or ICS-vilanterol for SMART strategy; only ICS-formoterol is appropriate for combined maintenance and reliever therapy 8
• Do not start with medium or high-dose ICS initially; low-dose provides optimal benefit-to-risk ratio 6
• Increasing ICS dose for increased symptoms is NOT recommended in patients likely to be adherent to daily ICS 1

Monitoring and Follow-Up

Assess control at each visit:

• Check adherence, inhaler technique, environmental factors, and comorbid conditions 1
• SABA use >2 days/week for symptom relief indicates inadequate control and need to step up treatment 1
• Reassess in 4-6 weeks after initiating or changing therapy 1
• Consider stepping down if asthma is well-controlled for at least 3 consecutive months 1

Specialist consultation:

• Consider consultation at Step 2 treatment 1
• Consult with asthma specialist if Step 3 or higher treatment is required 1